Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus - 1 Jan 2007

Pühringer-Oppermann F A, Stein H J, Sarbia M

Abstract excerpt

Epidermal growth factor receptor is over-expressed in several tumors and is the target for the tyrosine kinase inhibitor gefitinib. This receptor is also over-expressed in esophageal adenocarcinomas. In non-small cell lung cancer, specific somatic mutations residing in the epidermal growth factor receptor tyrosine kinase in the activation loop and the glycine-rich P-loop, are responsible for an enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Barrett Esophagus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Esophageal Neoplasms

Share to Gefitinib

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Source

Identifiers

PMID: 17227303
DOI: 10.1111/j.1442-2050.2007.00630.x

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.PMID 17227303Read ↗

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.Semantic proximity Read ↗

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Semantic proximity Read ↗

The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.Semantic proximity Read ↗

Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas.Semantic proximity Read ↗

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Semantic proximity Read ↗

Absence of epidermal growth factor receptor mutations in cervical cancer.Semantic proximity Read ↗

High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.Semantic proximity Read ↗

Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.Semantic proximity Read ↗

Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma.Semantic proximity Read ↗

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Identification of EGFR mutations in esophageal cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.